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TO THE EDITOR
Until recently, little was known about
the interpretability of scores of the
Skindex-29, a well-established, derma-
tology-specific health-related quality of
life (HRQoL) instrument (Chren et al.,
1997a, b). Nijsten et al. (2009) and
Prinsen et al. (2010, 2011) were the
first to identify the clinical meaningful-
ness of Skindex-29 scores by estimating
a categorization of Skindex-29 scores,
denoting mildly, moderately, and (very)
severely impaired HRQoL (Nijsten
et al., 2009; Prinsen et al., 2010, 2011).
In their thoughtful commentary in
the Journal of Investigative Dermatol-
ogy, 131, (9) September 2011, Sampog-
na and Abeni persuasively showed how
different methods, a distribution-based
and an anchor-based method, respec-
tively, result in different categoriza-
tions of scores (Sampogna and Abeni,
2011). They applied the distribution-
based ranges of scores found by Nijsten
et al. and the anchor-based cutoff
scores found by Prinsen et al. to an
Italian sample of inpatients diagnosed
with psoriasis, and to another Italian
sample of dermatological outpatients.
By means of this comparison, differ-
ences between the two categorizations
were shown; in general, the ranges of
scores presented by Nijsten et al. were
lower than the cutoff scores presented
by Prinsen et al. Sampogna and Abeni
also explored the clinical implications
of these differences, for instance the
consequence of using different cate-
gories in determining patient’s eligibil-
ity for systemic treatment.
Unfortunately, a misinterpretation
leading to an incorrect categorization
Table 1. An overview of the Skindex-291 cutoff scores derived by an anchor-based method (Prinsen et al.)2 and the
ranges of scores derived by a distribution-based method (Nijsten et al.)3
Symptoms Emotions Functioning Overall
Categorization Prinsen et al. Nijsten et al. Prinsen et al. Nijsten et al. Prinsen et al. Nijsten et al. Prinsen et al. Nijsten et al.
Very little — o3 — o5 — o3 — o5
Mild X39 4–10 X24 6–24 X21 4–10 X25 6–17
Moderate X42 11–25 X35 25–49 X32 11–32 X32 18–36
Severe X52 26–49 X39 450 X37 433 X44 437
Very severe — 450 — — — — — —
1The domain scores and the overall score are expressed on a 100-point scale, with higher scores indicating a lower level of quality of life.
2Skindex-29 cutoff scores are derived from the original articles (Prinsen et al., 2010, 2011).
3Categorization of Skindex-29 scores are derived from the original article (Nijsten et al., 2009).
Abbreviations: HRQoL, health-related quality of life
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of scores was made. To illustrate,
according to Prinsen et al., the cutoff
scores for mildly, moderately, and
severely impaired HRQoL on the emo-
tions domain were X24, X35, and
X39, respectively, meaning that a
patient with a score X24 can be catego-
rized as having a mildly impaired HRQoL
on this domain, a score X35 as ‘‘mode-
rate’’, etc. However, Samponga and
Abeni categorized ‘‘mild’’ as having a
score between 0 and 23.9 and, as a
consequence, misclassified all cutoff
scores. Therefore, we would like to pro-
vide a correct overview of the categor-
ization of Skindex-29 scores (Table 1).
Having said this, we fully agree with
Sampogna and Abeni on the limitations
of both methods, such as dependence
on the distribution of HRQoL scores in
estimation samples and biases when
using prospective anchors. Neverthe-
less, we believe that, under the condi-
tion that the same scale or anchor
question is being used, anchor-based
methods may lead to less variant
estimates of cutoff scores than distribu-
tion-based methods. In addition, an-
chor-based methods are less dependent
on the sociocultural and clinical char-
acteristics of the estimation sample. For
example, patients in one sample, scor-
ing themselves as having a severely
impaired HRQoL on a global rating
scale or anchor question (for instance,
an anchor question such as ‘‘In your
opinion, how severe is your skin con-
dition?’’), are likely to have Skindex-29
scores in the same range of scores as
patients of another sample who also
score themselves as having a severely
impaired HRQoL. Nevertheless, the
phrasing of an anchor question is a
great source of variation in the compar-
ison of different cutoff scores. We
therefore advocate the use of standard-
ized anchors.
A clinically meaningful interpreta-
tion of Skindex-29 scores is of great
value. At present, two studies on this
intriguing subject are available. As
already expressed by Sampogna and
Abeni, the combination of an anchor-
based and a distribution-based method
in a subsequent study would allow an
objective comparison of the results
within one study population. In addi-
tion to this, we recommend including
standardized anchors, and to conduct
such a study on an international level.
Eventually, such efforts will contribute
to reaching consensus on the catego-
rization of scores so that they can be
applied in clinical practice.
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TO THE EDITOR
Any delay in wound closure increases
the probability of developing dermal
fibrotic conditions such as hypertrophic
scars (Deitch et al., 1983). For patients
with extensive burn injuries, one of
the most promising approaches is the
application of an engineered skin sub-
stitute containing both epidermal and
dermal cells (Coulomb et al., 1998).
Where allogeneic skin substitutes can
provide a rapid, patient-ready wound
coverage, they are susceptible to im-
mune rejection. Our approach has been
to engineer an allogeneic skin substituteAbbreviations: IDO, indoleamine 2,3-dioxygenase; SEI, scar elevation index
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IDO-Expressing Skin Substitute Improves Scarring
